DNS - Dupilumab III
Economic Operator with Whom the Contract Has Been Concluded
| Show detail | ||||||||
|---|---|---|---|---|---|---|---|---|
| D00864/2022 + 14-73/2022-1470 | 30. 05. 2022 | sanofi-aventis, s.r.o. | 26 271 848,99 | 23 883 499,08 | 26 271 848,99 | 23 883 499,08 | CZK |
Published Documents
| Show detail | |||||
|---|---|---|---|---|---|
| D00864/2022 + 14-73/2022-1470 | VNOL odpoved_zverejneni - 2022-05-23T085241.956.pdf | Smlouva | 16. 06. 2022 15:23 | Dokument není zavirovaný | |
| D00864/2022 + 14-73/2022-1470 | VNOL Sanofi smlouva Dupixent.pdf | Smlouva | 16. 06. 2022 15:23 | Dokument není zavirovaný |
List of Participants
| Show detail | ||||||
|---|---|---|---|---|---|---|
| sanofi-aventis, s.r.o. | Praha |
Price Actually Paid in Each Year of Performance
| D00864/2022 + 14-73/2022-1470 | 2023 | 4 563 607,20 | 4 148 733,62 |
| D00864/2022 + 14-73/2022-1470 | 2022 | 3 791 774,61 | 3 447 067,36 |